Sorrento Hits Snag On $200M Scilex Stock Sale In Ch. 11

By Vince Sullivan · August 1, 2023, 7:27 PM EDT

Bankrupt drug developer Sorrento Therapeutics told a Texas judge Tuesday that its planned $200 million sale of its equity in nondebtor subsidiary Scilex Holding Co. had hit a snag, forcing the...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Bankruptcy Scorecard

Summary

California biopharmaceutical firm Sorrento Therapeutics Inc., filed for Chapter 11 protection with about $135 million in debt, in the face of a $175 million arbitration award.

Case Number

4:23-bk-90085

Judge

Christopher M. Lopez

Venue

U.S. Bankruptcy Court for the Southern District of Texas

Capital Structure

View Full Scorecard

Related Sections

Case Information

Case Title

Sorrento Therapeutics, Inc.

Case Number

4:23-bk-90085

Court

Texas Southern

Nature of Suit

Date Filed

February 13, 2023

Recent Articles By Vince